Skip to content


  • Oral presentation
  • Open Access

Circulating tumor and endothelial cells as predictors of response in metastatic breast cancer

  • 1
Breast Cancer Research20079 (Suppl 1) :S3

  • Received: 23 May 2007
  • Published:


  • Metastatic Breast Cancer
  • Medical Oncology
  • Primary Breast Cancer
  • Circulate Tumor Cell
  • Prognostic Implication

The detection of microscopic disease is associated with prognostic implications in primary breast cancer [1]. In metastatic breast cancer (MBC), reliable detection of circulating tumor cells (CTCs) has been obtained using immunomagnetic separation and subsequent analysis by the CellSpotter™ analyzer (Veridex LLC, a Johnson & Johnson company, Warren, NJ, USA) [2, 3]. This technology is becoming a standard tool for the 'real-time' assessment of prognosis and response to treatment [4, 5]. The detection of CTCs in patients with MBC about to start a new line of treatment has been shown to predict progression-free survival and overall survival and treatment benefit. The prognostic value was independent of the line of therapy (for example, first line versus second line or more) [2, 3]. Moreover, in multivariate analysis CTCs demonstrated superior value compared with the site of metastasis (for example, visceral versus soft tissue/bone), type of therapy, and length of time to recurrence after definitive primary surgery. Furthermore, the prognostic value of CTCs has been shown to be superior to standard tumor markers (for example, Ca27-29), tumor burden and phenotype of disease [6]. We have recently focused on determining the feasibility of the genotypic characterization of CTCs and correlating with the expression of similar genes in primary or metastatic lesions [7].

Increases in the number of circulating endothelial cells (CECs) and progenitors (CEPs) have been reported in various pathological conditions including cancer [8, 9]. At the clinical level, evidence is emerging that CEC kinetics and viability might correlate with clinical outcomes in cancer patients who undergo anti-angiogenic treatment [10]. The CellSpotter™ analyzer is also being investigated for measurement and characterization of CEC [11]. Therefore, CEC and CEP measurement has potential as a surrogate marker for monitoring anti-angiogenic treatment and drug activity, and could help to determine the optimal biological dose of anti-angiogenic drugs, which are being used with increasing frequency in medical oncology.

Authors’ Affiliations

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA


  1. Braun S, Pantel K, Müller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med. 2000, 342: 525-533. 10.1056/NEJM200002243420801.View ArticlePubMedGoogle Scholar
  2. Cristofanilli M, Budd GT, Ellis M, et al: Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer. N Engl J Med. 2004, 351: 781-791. 10.1056/NEJMoa040766.View ArticlePubMedGoogle Scholar
  3. Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005, 23: 1420-1430. 10.1200/JCO.2005.08.140.View ArticlePubMedGoogle Scholar
  4. Hayes DF, Cristofanilli M, Budd GT, et al: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006, 12: 4218-4224. 10.1158/1078-0432.CCR-05-2821.View ArticlePubMedGoogle Scholar
  5. Budd GT, Cristofanilli M, Ellis M, et al: Circulating tumor cells versus imaging – predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006, 12: 6403-6409. 10.1158/1078-0432.CCR-05-1769.View ArticlePubMedGoogle Scholar
  6. Cristofanilli M, Kristine Broglio KR, Guarneri V, et al: Circulating tumor cells in metastatic breast cancer (MBC): biological staging beyond tumor burden. Clin Breast Cancer. 2007, 7: 471-479.View ArticlePubMedGoogle Scholar
  7. Reuben JM, Lee B-N, Li C, et al: Genomic of circulating tumor cells in metastatic breast cancer [abstract]. ASCO. 2007,Google Scholar
  8. Cines DB, et al: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998, 91: 3527-3561.PubMedGoogle Scholar
  9. Mancuso P, et al: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001, 97: 3658-3661. 10.1182/blood.V97.11.3658.View ArticlePubMedGoogle Scholar
  10. Mancuso P, et al: Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood. 2006, 108: 452-459. 10.1182/blood-2005-11-4570.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Smirnov DA, Foulk BW, Doyle GV, et al: Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res. 2006, 66: 2918-2922. 10.1158/0008-5472.CAN-05-4003.View ArticlePubMedGoogle Scholar


© BioMed Central Ltd 2007